Infinimmune, Grid Therapeutics form partnership for deep sequencing of B cells for NSCLC drug discovery

Datopotamab deruxtecan did not reach statistical significance for OS in metastatic or advanced nonsquamous NSCLC in phase III trial

Topline overall survival results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy.

May 31, 2024

Vol.50 No.22

Drugs & Targets

Cartography, Gilead collaborate to develop therapies for breast and lung cancers

Cartography Biosciences Inc. has entered a strategic collaboration agreement with Gilead Sciences Inc., to discover and develop therapies for patients with triple-negative breast cancer and the most common form of non-small cell lung cancer, adenocarcinoma.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Lifileucel shrinks tumors in mNSCLC in phase II trial

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

Patients with KRASG12C mutated-non-small cell lung cancer who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings presented during an April 30 session of the American Society of Clinical Oncology Plenary Series.

May 03, 2024

Vol.50 No.18

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Infinimmune, Grid Therapeutics form partnership for deep sequencing of B cells for NSCLC drug discovery

YOU MAY BE INTERESTED IN

Datopotamab deruxtecan did not reach statistical significance for OS in metastatic or advanced nonsquamous NSCLC in phase III trial

Cartography, Gilead collaborate to develop therapies for breast and lung cancers

Lifileucel shrinks tumors in mNSCLC in phase II trial

Glecirasib shows positive ORR for KRASG12C mutated-NSCLC in phase II trial

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Renew today!

Subscriber content

Login